PlainRecalls
FDA Drug Moderate Class II Terminated

Memantine Hydrochloride Extended Release Capsules, 21 mg, 30-count bottles, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 United States. Manufactured by: Lupin Limited Pithampur (M.P.)-454 775, INDIA, NDC 68180-248-06

Reported: February 19, 2020 Initiated: February 12, 2020 #D-0855-2020

Product Description

Memantine Hydrochloride Extended Release Capsules, 21 mg, 30-count bottles, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 United States. Manufactured by: Lupin Limited Pithampur (M.P.)-454 775, INDIA, NDC 68180-248-06

Reason for Recall

Failed Dissolution Specifications: Low out of specification results observed in dissolution test at six-month long-term stability study.

Details

Units Affected
6,294 bottles
Distribution
Nationwide within the United States.
Location
Baltimore, MD

Frequently Asked Questions

What product was recalled?
Memantine Hydrochloride Extended Release Capsules, 21 mg, 30-count bottles, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 United States. Manufactured by: Lupin Limited Pithampur (M.P.)-454 775, INDIA, NDC 68180-248-06. Recalled by Lupin Pharmaceuticals Inc.. Units affected: 6,294 bottles.
Why was this product recalled?
Failed Dissolution Specifications: Low out of specification results observed in dissolution test at six-month long-term stability study.
Which agency issued this recall?
This recall was issued by the FDA Drug on February 19, 2020. Severity: Moderate. Recall number: D-0855-2020.